article thumbnail

Thursday pharma headlines

World of DTC Marketing

regulators knew about reports of suicidal behavior in men taking the anti-baldness treatment Propecia when they decided not to warn consumers of those potential risks in a 2011 update of the popular drug’s label. The national vaccine safety surveillance program run by the Centers for Disease Control and Prevention (CDC) and the U.S.

Pharma 180
article thumbnail

FDA extends review of GSK’s myelofibrosis drug

Pharmaceutical Technology

The trial’s data readout found that the momelotinib group had a favourable safety profile and the drug caused clinically significant improvements in myelofibrosis-associated symptoms, anaemia symptoms, and more, in comparison to the danazol group.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In August 2021, Saphnelo, a type 1 interferon receptor antibody, became the first lupus treatment to be approved since GSK’s Benlyta (belimumab) won a regulatory nod in 2011. The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson. MSCs and CAR-Ts for lupus.

article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

Caregiver observations of the patient experience over the progression of the disease may inform the safety and efficacy of a particular therapeutic. The FDA has studied the importance of caregivers to drug development and regulatory decision-making. Findings note that caregivers are a vital source of information. February 2019. Public Health.

Pharma 98
article thumbnail

Why Are Patients So Angry? Plus, Frontliner Tips for Health Leaders

Healthcare Success

The rate of injuries from violent attacks against medical professionals grew by 63% from 2011 to 2018. To be clear, workplace violence experienced by healthcare workers predates the pandemic. However, these numbers escalated in 2020, along with the COVID-19 pandemic. Why are people so angry and rude? How did we get here?

Patients 105
article thumbnail

Re-engineering proteins to develop novel immunotherapies

European Pharmaceutical Review

IL-2 therapy is associated with safety concerns, namely the adverse event capillary leak syndrome, which often leads to hospitalisations and thus limits its clinical use. 2011; 117(11): 2993–3001. Although IL-2 was recognised as an efficacious treatment, clinical use was limited by toxicity issues. References Alduaij W, Illidge T.

article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

7 It is currently being evaluated in a Phase Ib/IIa clinical study, demonstrating to date a good safety profile. While favourable safety has been reported up to the Phase II, the relevance of targeting the C-terminal portion of Abeta still needs to be confirmed.